NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Revolution Medicines, Inc. (RVMD) Stock Analysis

Revolution Medicines, Inc. (RVMD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RVMD

$194.28

−$2.27 (−1.15%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RVMD with… →

RVMD Key Statistics

As of Oct 21, 2026
Trading
Open
$198.71
Previous Close
$196.55
Day's Range
193.97–203.49
52-Week Range
52.48–224.31
Volume
1.88M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.40
Valuation
Market Cap
$41.64B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−8.87
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$1.13B
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
214.34M
1-Year Return
+263.21%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
1.97M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RVMD closed at $194.28, +263.21% over 1 year.

Revolution Medicines, Inc. (RVMD) has a market capitalization of $41.64B.

In fiscal 2025, RVMD reported revenue of $0.00.

RVMD Stock Return by Calendar Year

Revolution Medicines, Inc. (RVMD) return since Feb 2020: what $10,000 became

1 year
$10,000 $36,321
+263.21%
5 years
$10,000 $71,087
+610.87%
Since Feb 2020
$10,000 $67,225
+572.25%

If you had invested $10,000 in Revolution Medicines, Inc. (RVMD) at the close on February 13, 2020, the earliest close on record here, it would have been worth $67,225 at the close on October 21, 2026: +572.25% in total, +32.98% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+143.92%
2025+82.10%
2024+52.51%
2023+20.40%
2022−5.36%
2021−36.42%
2020 (partial year)+36.99%

As of October 21, 2026.

RVMD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$1.13B—
2024$0.00−$600.09M—
2023$11.58M−$436.37M−3,768.3%
2022$35.38M−$248.71M−703.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$1.18B−$1.13B—
2024$0.00—−$689.52M−$600.09M—
2023$11.58M—−$487.19M−$436.37M−3,768.3%
2022$35.38M—−$258.28M−$248.71M−703.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Revolution Medicines, Inc. (RVMD) carries a market capitalisation of $41.64B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 883.

RVMD last closed at $194.28 on October 21, 2026. That is −$2.27 (−1.15%) against the previous close. Over the past 52 weeks the price has ranged from $52.48 to $224.31. The latest close sits 270.2% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $1.13B. Trailing earnings per share are −8.87.

Across the 4 fiscal years on file, revenue moves from $35.38M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is +263.21%. Measured over 5 years, that is +48.03% a year compounded. Beta against the wider market is reported at 1.4. Annualized volatility over the trailing 6 years is 61.86%.

Growth & Income

The record shows no dividend for RVMD.

The strongest complete calendar year on file is 2025 at +82.10%; the weakest is 2021 at −36.42%. Of the 5 complete calendar years on file, 3 finished higher. So far in 2026 the total return is +143.92%.

Peer Comparison

Revolution Medicines, Inc. (RVMD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Revolution Medicines, Inc. RVMD $41.64B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Revolution Medicines, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RPRX

Royalty Pharma plc

$35.91B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Visit website →